| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Launched Niagen NanoCloud™, the first dermatologist-tested topical product |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July |
| 29 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Set forth below are the results of the matters submitted for a vote of stockholders at the Company’s 2026 Annual Meeting. |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million |
| 19 Mar 2026 |
8-K: Other Events
LOS ANGELES – March 19, 2026 – Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authori... |
| 04 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction |
| 22 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain information in this document (indicated by [***]) has been excluded pursuant to Regulation S-K Item 601(b)(10). Such information is not material and is treated by the Registrant as private or confidential. |
| 06 Nov 2025 |
8-K: Other Events
LOS ANGELES – November 6, 2025 – Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has appro... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Net income of $4.6 million, up $2.7 million from the prior year |
| 06 Oct 2025 |
8-K: Regulation FD Disclosure
LOS ANGELES--October 6, 2025-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has increased its full-year 2025 net... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Net income of $3.6 million versus breakeven in prior year period |
| 29 Jul 2025 |
8-K: Entry into a Material Definitive Agreement
Certain information in this document (indicated by [***]) has been excluded pursuant to Regulation S-K Item 601(b)(10). Such information is not material and is treated by the Registrant as private or confidential. |
| 27 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a)Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Niagen Bioscience, Inc. Second Amended and Restated 2007 Equity Incentive Plan, (the “2007 Plan”). Following the Effective D... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. |
| 19 Mar 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
Section 1. Registered Office. The registered office of the Corporation in the State of Delaware shall be in the Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware, 19801 and the name o... |
| 04 Mar 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash an... |
| 27 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
ChromaDex Corporation (the “Company”), pursuant to its 2017 Equity Incentive Plan (as amended from time-to-time, the “Plan”), hereby awards to Participant a performance stock unit award that grants Participant the right to receive the nu... |
| 16 Dec 2024 |
8-K: Changes in Registrant's Certifying Accountant
Following a competitive request-for-proposal process during which the Audit Committee of our Board of Directors (the “Audit Committee”) solicited and reviewed proposals from several accounting firms, the Audit Committee approved the enga... |
| 04 Dec 2024 |
8-K: Other Events
On November 27, 2024, ChromaDex, Inc. (“ChromaDex”), a wholly-owned subsidiary of ChromaDex Corporation, entered into a Supplemental Agreement (the “Supplemental Agreement”) with the Trustees of Dartmouth College (“Dartmouth,” and togeth... |
Loading...